Dissatisfaction in atopic dermatitis treatment revealed; clear opportunities for new entrants

Size: px

Start display at page:

Download "Dissatisfaction in atopic dermatitis treatment revealed; clear opportunities for new entrants"

Derek Kerry Jordan
5 years ago
Views:

Press release Embargo date: June 9, 2015 June 9, 2015 Contact Ben Walton ben.walton@gfk.

1 Press release Embargo date: June 9, 2015 June 9, 2015 Contact Ben Walton Dissatisfaction in atopic dermatitis treatment revealed; clear opportunities for new entrants For moderate to severe adult patients treated with high potency topical steroids, over four out of 10 physicians and six out of 10 patients are not satisfied with the level of control achieved. GfK SE Nordwestring Nuremberg Germany Tel Fax Management Board: Matthias Hartmann (CEO) Christian Diedrich (CFO) Dr. Gerhard Hausruckinger Debra A. Pruent Chairman of the Supervisory Board: Dr. Arno Mahlert Commercial register Nuremberg HRB percent of moderate to severe adults receiving high potency topical steroids are expected to repeat this same treatment. Nuremberg, June 9, 2015 Latest results from GfK Disease Atlas, a real-world evidence program linking physician- and patient-reported treatment data, reveals major gaps in satisfaction levels for the treatment of atopic dermatitis. The international survey of physicians and patients shows that 43 percent of physicians treating moderate to severe adult atopic dermatitis patients with high potency topical steroids are not satisfied with the level of control achieved. And dissatisfaction among the patients themselves stands at 66 percent. Worse yet, patients expect to be dissatisfied: 92 percent agree that their doctor explained to them what to expect from this treatment. Results also reveal repeated use of high potency topical steroids among moderate to severe adult patients, with 91 percent receiving this therapy set to repeat this treatment, according to the prescribing physician. These same patterns are seen with another common therapy for moderate to severe atopic dermatitis: oral steroids, with similar high dissatisfaction levels amongst physicians and patients, and similar repeat use. The lack of new therapies for atopic dermatitis means that patients are often cycled through the same old treatment options, such as topical steroids and oral steroids, said Alison Rose, Immunology & Dermatology Therapy Director at GfK. But the low satisfaction level with these habitual treatments that we are seeing among both doctors and patients indicates huge potential for any players entering this market with new therapy options. GfK will be sharing further insights on dermatology at the World Congress of Dermatology June 8-13 in Vancouver, Canada, via a Feature Poster on Analysis of physician and patient perceptions of chronic hand eczema a global survey. 1

2 For more information on the Disease Atlas program on atopic dermatitis or similar Disease Atlas programs for acne, psoriasis or rheumatology, please contact Ben Walton at or About the research survey The GfK Disease Atlas for atopic dermatitis covers eight countries, delivering patient level data from over 4,000 pediatric and adult atopic dermatitis patients, together with insights from over 800 physicians. About GfK GfK is the trusted source of relevant market and consumer information that enables its clients to make smarter decisions. More than 13,000 market research experts combine their passion with GfK s long-standing data science experience. This allows GfK to deliver vital global insights matched with local market intelligence from more than 100 countries. By using innovative technologies and data sciences, GfK turns big data into smart data, enabling its clients to improve their competitive edge and enrich consumers experiences and choices. For more information, please visit or follow GfK on Twitter: Responsible under press legislation: GfK SE, Global Communications Jan Saeger Nordwestring Nuremberg Germany press@gfk.com 2

3 ATOPIC DERMATITIS PATIENTS, PHYSICIANS EXPRESS LOW SATISFACTION WITH TREATMENTS Physician-reported Patient-reported For moderate to severe adults, % of physicians and patients not satisfied with control achieved with treatment regimen 66% 73% 43% 48% Oral

4 REPEATED USE OF HIGH POTENCY TOPICAL STEROIDS AND ORAL STEROIDS Of moderate to severe adult atopic dermatitis patients, % who will receive same treatment again (according to treating physician) Oral 91% 85%

5 PATIENTS EXPECT TO BE DISSATISFIED Among moderate to severe adult atopic dermatitis patients receiving high potency topical steroids, 92% of patients agree their physician explained to them what to expect with their treatment 92%

REFERENCE CODE GDHC295DFR PUBLICATION DATE NOVEMBER 2013 ELIDEL (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC295DFR PUBLICATION DATE NOVEMBER 2013 ELIDEL (ATOPIC DERMATITIS) Executive Summary The below mentioned table presents key metrics for Elidel in the major pharmaceutical markets: the